Skip to main content

KILL Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials

 

Aditxt, Inc. requests that their press release NewsItemId: 20250414955183 issued April 14, 2025 “Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials” be killed.

The release was issued in error by Aditxt, Inc.

A replacement release will not be issued at this time.

Contacts

Aditxt, Inc. 

Corporate Communications 

Jeff Ramson, PCG Advisory, Inc. 

T: 646-863-6893 

contactus@aditxt.com

Recent Quotes

View More
Symbol Price Change (%)
AMZN  209.79
+1.23 (0.59%)
AAPL  274.51
+2.38 (0.87%)
AMD  212.85
-0.99 (-0.46%)
BAC  51.67
+1.27 (2.51%)
GOOG  310.59
-0.33 (-0.11%)
META  650.04
+10.74 (1.68%)
MSFT  399.63
+10.63 (2.73%)
NVDA  196.97
+4.12 (2.13%)
ORCL  150.20
+4.06 (2.78%)
TSLA  415.98
+6.60 (1.61%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.